Dr. Daniel Dickerson

Family Medicine
Office
9755 Ridge Dr, 
Lenexa, KS 
Office
9755 Ridge Dr, 
Lenexa, KS 

Overview

Daniel Dickerson is a primary care provider, practicing in Family Medicine in Lenexa, Kansas.

His clinical expertise encompasses Parainfluenza.

He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 13 clinical trials.

Specialties

Family Medicine

Licenses

Family Medicine in KS

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
View 1 Less Insurance Carrier -

Locations

Office
9755 Ridge Dr, Lenexa, KS 66219

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and PK of LY3541105 Following Single Doses in Healthy/Overweight Participants and Multiple Doses in Overweight Participants
A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and PK of LY3541105 Following Single Doses in Healthy/Overweight Participants and Multiple Doses in Overweight Participants
Enrollment Status: Completed
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Single-Center, Dose-Escalation Study to Determine the Safety and Pharmacokinetics of a Single Oral Dose of PF614 in Healthy Subjects Compared to OxyContin®
A Phase 1, Single-Center, Dose-Escalation Study to Determine the Safety and Pharmacokinetics of a Single Oral Dose of PF614 in Healthy Subjects Compared to OxyContin®
Enrollment Status: Completed
Publish Date: October 02, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
Enrollment Status: Completed
Publish Date: October 27, 2022
Intervention Type: Other, Drug
Study Phase: Phase 1
A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EDP 514 in Healthy Subjects (Part 1), and Antiviral Activity in Nucleos(t)Ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients With Chronic Hepatitis B Virus Infection (Part 2)
A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EDP 514 in Healthy Subjects (Part 1), and Antiviral Activity in Nucleos(t)Ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients With Chronic Hepatitis B Virus Infection (Part 2)
Enrollment Status: Completed
Publish Date: January 11, 2022
Intervention Type: Drug
Study Drug: EDP-514
Study Phase: Phase 1
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of EDP-938 on the Pharmacokinetics of Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of EDP-938 on the Pharmacokinetics of Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects
Enrollment Status: Completed
Publish Date: October 13, 2021
Intervention Type: Drug
Study Drugs: EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, Midazolam
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328
Enrollment Status: Completed
Publish Date: May 25, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: January 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
Enrollment Status: Completed
Publish Date: June 14, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Cyclosporine and Prednisone on the Pharmacokinetics and Safety of EDP-938 in Healthy Adult Subjects
A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Cyclosporine and Prednisone on the Pharmacokinetics and Safety of EDP-938 in Healthy Adult Subjects
Enrollment Status: Completed
Publish Date: February 12, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

11 Total Publications

Bioequivalence Between a Gantenerumab Disposable Syringe and an Autoinjector: A Randomized Controlled Trial in Healthy Volunteers.
Bioequivalence Between a Gantenerumab Disposable Syringe and an Autoinjector: A Randomized Controlled Trial in Healthy Volunteers.
Journal: Clinical pharmacology in drug development
Published: November 28, 2025
Similar Doctors
Expertise in
6
conditions
Dr. Dennis M. Jensen
Family Medicine
Expertise in
6
conditions
Dr. Dennis M. Jensen
Family Medicine

Optum Medical Group PA

6860 W 115th St, 
Overland Park, KS 
 (6.5 miles away)
913-253-0601
Languages Spoken:
English
See accepted insurances

Dennis Jensen is a primary care provider, practicing in Family Medicine in Overland Park, Kansas. Dr. Jensen is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Gastrointestinal Bleeding, Peptic Ulcer, Mesenteric Artery Ischemia, Colonoscopy, and Endoscopy.

Expertise in
70
conditions
Dr. Neal A. Erickson
Family Medicine
Expertise in
70
conditions
Dr. Neal A. Erickson
Family Medicine

Ascentist Management

4550 W 109th St Ste 200, 
Overland Park, KS 
 (7.8 miles away)
913-721-3387
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Neal Erickson is a primary care provider, practicing in Family Medicine in Overland Park, Kansas. Dr. Erickson is highly rated in 70 conditions, according to our data. His clinical expertise encompasses Hypertension, Familial Hypertension, Glucocorticoid-Remediable Aldosteronism, Colonoscopy, and Vertebroplasty.

Expertise in
39
conditions
Dr. John Armilio
Family Medicine
Expertise in
39
conditions
Dr. John Armilio
Family Medicine

Overland Park Regional Medical Center

10500 Quivira Rd, 
Lenexa, KS 
 (2.9 miles away)
913-541-5000
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

John Armilio is a primary care provider, practicing in Family Medicine in Lenexa, Kansas. He has been practicing medicine for over 17 years. Dr. Armilio is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Necrosis, Enlarged Liver, Ogilvie Syndrome, Cardiac Ablation, and Endoscopy.

Frequently Asked Questions about Dr. Daniel Dickerson

How do I make an appointment with Dr. Daniel Dickerson?

You can book an appointment with Dr. Daniel Dickerson by calling their office at 913-410-2973. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel Dickerson a top-rated expert for Parainfluenza?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel Dickerson is classified as an Experienced expert for Parainfluenza, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel Dickerson specialize in?

While Dr. Daniel Dickerson is a Family Medicine, they have specific expertise in Parainfluenza. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Family Medicine.

Does Dr. Daniel Dickerson participate in research or clinical trials?

Yes. Dr. Daniel Dickerson has published 11 articles and abstracts on conditions like Parainfluenza. You can view a list of Dr. Daniel Dickerson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel Dickerson accept my insurance?

Dr. Daniel Dickerson accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 913-410-2973 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dickerson's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile